EagleClaw Capital Managment LLC lifted its stake in Cigna Corp (NYSE:CI) by 13.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,135 shares of the health services provider’s stock after purchasing an additional 1,449 shares during the period. EagleClaw Capital Managment LLC’s holdings in Cigna were worth $1,841,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of CI. Redhawk Wealth Advisors Inc. purchased a new stake in Cigna in the 2nd quarter worth $28,000. Virtus ETF Advisers LLC purchased a new stake in Cigna in the 2nd quarter worth $30,000. Garrett Wealth Advisory Group LLC purchased a new stake in Cigna in the 3rd quarter worth $30,000. Optimum Investment Advisors increased its stake in Cigna by 258.6% in the 3rd quarter. Optimum Investment Advisors now owns 208 shares of the health services provider’s stock worth $32,000 after buying an additional 150 shares in the last quarter. Finally, TRUE Private Wealth Advisors purchased a new stake in Cigna in the 2nd quarter worth $40,000. Hedge funds and other institutional investors own 87.45% of the company’s stock.
Shares of CI traded up $5.41 during midday trading on Tuesday, hitting $172.15. 82,706 shares of the company traded hands, compared to its average volume of 2,167,046. The firm has a 50 day moving average of $156.46 and a 200-day moving average of $159.20. Cigna Corp has a 52 week low of $141.95 and a 52 week high of $226.60. The stock has a market cap of $63.29 billion, a price-to-earnings ratio of 12.10, a PEG ratio of 0.85 and a beta of 0.71. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.70 and a current ratio of 0.70.
In other Cigna news, CEO David Cordani purchased 32,509 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average price of $155.17 per share, with a total value of $5,044,421.53. 0.80% of the stock is owned by corporate insiders.
CI has been the subject of a number of analyst reports. Deutsche Bank initiated coverage on Cigna in a research note on Thursday, September 12th. They issued a “buy” rating and a $207.00 price target for the company. Raymond James increased their price target on Cigna from $185.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Sanford C. Bernstein upgraded Cigna from a “market perform” rating to an “outperform” rating and set a $205.00 price target for the company in a research note on Tuesday, August 6th. Citigroup reiterated a “buy” rating on shares of Cigna in a research note on Wednesday, August 21st. Finally, ValuEngine upgraded Cigna from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $208.96.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Featured Article: Dividend
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.